In this issue:
Bevacizumab + erlotinib promising for HLRCC
CONTACT-02: TKI/checkpoint inhibitor combo vs ARPI switch in mCRPC
PSMAfore: Health-related quality of life benefits to 177Lu-PSMA-617 in mCRPC
6p22.3 amplification genotype linked to better prognosis after treatment in MIBC
EV combo bests chemo for urothelial cancer regardless of location of metastases
Modest antitumor activity for nemvaleukin in RCC
Use of ADT alone still common for mHSPC in the US
OpeRa trial fails to show less complications with robotic- vs open surgery for renal tumours
Refining indications for post-chemotherapy RPLND in metastatic non-seminomatous GCTs
Open vs robot-assisted minimally invasive RPLND for testicular can
Please login below to download this issue (PDF)